Premium Alert - 9/1 (NASDAQ: BNOX) Gets “Buy” Rating Target $17 (844% Upside Potential)

BNOX is Trading Premarket Right Now - Very Bullish Signal Your New Premium Alert Is Bionomics (NASDAQ: BNOX) This $1.65 Red Hot Biotech Gets $17.00 Price Target by Wall Street Analyst Hi 10XProTrader Member, This is Kevin Vander with “10XProTrader” delivering you your new premium alert for Friday 9/1 trading session is Bionomics Limited (NASDAQ: BNOX). BNOX is trading pre-market right now signaling a very bullish breakout! This stock has a Bullish 844% potential upside from its current price according to Wall Street analyst. The stock is trading under $1.65/share and has 5 Wall Street analysts predicting monstrous upside potential to as high as $17.00/share 12 - month forecast! That Equates to a Potential Gain of 844% (Based on Wall Street Analyst) > [See Stock Price Forecast of $17.00 or 844%]( Gain < Bionomics Limited (NASDAQ: BNOX) is a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. Bionomics Limited is advancing their lead product candidate, BNC210, an oral proprietary selective NAM of the α7 receptor, for the acute treatment of Social Anxiety Disorder (“SAD”) and chronic treatment of Post-Traumatic Stress Disorder (“PTSD”). There remains a significant unmet medical need for the over 22 Million patients in the United States alone suffering from SAD and PTSD. Bullish Catalyst Loop Capital Analyst Issued a Buy rating on Bionomics Limited with a price target of $17.00. Initiating with Buy Rating and $17.00 PT According to Loop Capital Markets Analyst, Bionomics Limited (NASDAQ: BNOX) has 844% upside potential, based on the analysts’ price target. Bullish Catalyst Maxim Group Analyst Issued a Buy rating on Bionomics Limited with a price target of $7.00. Initiating with Buy Rating and $7.00 PT According to Maxim Group Analyst, Bionomics Limited (NASDAQ: BNOX). has 288% upside potential, based on the analysts’ price target. Bullish Catalyst Cantor Fitzgerald Analyst Issued a Buy rating on Bionomics Limited with a price target of $8.00. Initiating with Buy Rating and $8.00 PT According to Cantor Fitzgerald Analyst, Bionomics Limited (NASDAQ: BNOX). has 344% upside potential, based on the analysts’ price target. Bullish Catalyst Evercore ISI Analyst Issued a Buy rating on Bionomics Limited with a price target of $6.00. Initiating with Buy Rating and $6.00 PT According to Evercore ISI Analyst, Bionomics Limited (NASDAQ: BNOX). has 233% upside potential, based on the analysts’ price target. Current pharmacological treatments include certain antidepressants and benzodiazepines, and there have been no new FDA approved therapies in these indications in nearly two decades. These existing treatments have multiple shortcomings, such as a slow onset of action of antidepressants, and significant side effects of both classes of drugs. BNC210 has been observed in our clinical trials to have a fast onset of action and demonstrated anti-anxiety and antidepressant effects without the limiting side effects seen with the current standard of care. Bionomics headquarters are located at 200 Greenhill Road, Eastwood, South Australia 5063, Australia, where we lease approximately 435 square meters of office space. The lease for our headquarters expires in May 31, 2026. We believe that our existing facilities are adequate for our near-term needs. We believe that suitable additional or alternative space would be available if required in the future on commercially reasonable terms. Bionomics (NASDAQ: BNOX) Has Caught The Attention of Institutional Hedge Funds Seeking Game-Changing Innovation A hedge fund recently bought a new stake in Bionomics stock. Point72 Asset Management L.P. bought a new position in Bionomics (NASDAQ: BNOX– Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 128,000 shares of the company’s stock, valued at approximately $595,000. Point72 Asset Management L.P. owned approximately 1.57% of Bionomics at the end of the most recent reporting period. 3.24% of the stock is owned by institutional investors and hedge funds. Bionomics (NASDAQ: BNOX) Aggressive Growth Strategy Bionomics goal is to be a leading biopharmaceutical company focused on the development and commercialization of novel, first-in-class treatments to transform the lives of patients with serious CNS disorders with high unmet medical need. The key elements of our strategy include: - Rapidly progress our lead product candidate, BNC210, through clinical development and to commercialization, if approved, for the acute treatment of patients with SAD. Our lead product candidate, BNC210, is an oral, proprietary, selective NAM of the α7 receptor designed to normalize the neurotransmitter imbalance and address anxiety and stressor-related disorders. Based on the favorable rapid absorption profile of our novel tablet formulation and evidence of anti-anxiety effect from our prior Phase 2 GAD trial, we believe there is a strong clinical and translational rationale to advance BNC210 for the acute treatment of patients with SAD, which we believe now has a defined clinical and regulatory pathway based on the FDA’s prior support of using a public speaking challenge as a registrational endpoint. We intend to file an investigational new drug application (“IND”) with the FDA in to conduct a Phase 2 clinical trial with BNC210 for the acute treatment of SAD. - Expand indication potential for BNC210 to other acute and chronic anxiety and stressor-related disorders. Based on what we believe is the novel mechanism of action of BNC210, the favorable safety data observed in approximately 400 subjects to date in 12 clinical trials and the broad utility of negative allosteric modulators of the α7 receptor, we believe BNC210 has the potential to address a wide-range of anxiety and stressor-related CNS disorders beyond acute treatment of SAD and chronic treatment of PTSD. We intend to continue evaluating BNC210’s potential for acute and chronic treatment of additional anxiety indications such as GAD, panic disorder and chronic treatment of SAD. - Build a commercialization infrastructure in the United States for BNC210. We have retained global development and commercialization rights to BNC210 and intend to maximize its commercial oppor∙tunity across global markets. We currently intend to build a focused commercial organization in the United States to market BNC210, if approved. Outside the United States, we will evaluate strategic oppor∙tunities to maximize the commercial potential of BNC210 with collaborators whose development and commercial capabilities complement our own. - Maximize the potential of our CNS programs and legacy oncology assets through selective partnerships and licensing. We have generated a series of product candidates that may have transformative potential across a range of CNS indications through our expertise in ion channels and, specifically, α7 receptors. We have an ongoing partnership with Merck for our α7 receptor PAM program to treat patients with cognitive impairment associated with Alzheimer’s disease and other CNS conditions. In addition, we have a collaboration with EmpathBio for feasibility studies to evaluate a combination of EMP-01, an MDMA derivative, and BNC210 as an adjunct to behavioral therapy, for the treatment of PTSD. We have also used our expertise in ion channel biology to identify multiple series of Nav1.7/1.8 inhibitors and Kv3.1/3.2 activators with transformative potential for patients suffering from pain and cognitive disorders, respectively, which we plan to leverage for future partnerships or licensing. In addition, we expect to continue to advance our legacy oncology programs through existing and future external funding and out-licensing to capture potential value for our shareholders. - Continue to strategically expand our clinical pipeline through acquisitions, licenses, and/or collaborations. We intend to take advantage of our management team’s substantial expertise in translational medicine and clinical development of drugs for psychiatric and neurological disorders to identify and in-license or acquire additional clinical-stage innovative therapies for diseases within CNS. Bionomics (NASDAQ: BNOX) Aligns Itself With Global Giant Research Collaboration and License Agreement with Merck Under the 2014 Merck License Agreement, Merck will fund all research and development, including clinical development, and worldwide commercialization of the licensed products. Pursuant to the 2014 Merck License Agreement, we received upfront payments totaling US$20Mln, and another US$10Mln in February 2017 when the first compound from the collaboration entered Phase 1 clinical trials and we are eligible to receive up to an additional US$465Mln in milestone payments for achievement of certain development and commercial milestones. Further, Merck is obligated to pay us tiered royalties in the mid single digit to low double digit percentage range on net sales of the licensed products, subject to reduction upon certain events. Merck’s royalty obligations will continue on a licensed product-by-licensed product and country-by-country basis until the later of (i) the last-to-expire valid patent claim claiming the applicable licensed compound contained in such licensed product as a composition of matter in such country or (ii) 10 years after the first commercial sale of such licensed product in such country. Any royalties payable pursuant to the 2014 Merck License Agreement (net of any required taxes payable by us) will be paid to holders of the contingent value right (“CVR”) to be issued to existing investors prior to the consummation of this offering. As a result, such royalties will not be retained by us or accrue to the benefit of investors who purchase ADSs. Bionomics (NASDAQ: BNOX) Aligns Itself With Another Pharma Research and License Agreement with Ironwood Pharmaceuticals In January 2012, we entered into a research and license agreement with Ironwood Pharmaceuticals, Inc. (“Ironwood”), pursuant to which Ironwood was granted worldwide development and commercialization rights for BNC210. In November 2014, the parties mutually agreed to terminate this license agreement, reverting all rights to BNC210 back to us. The sole obligation to Ironwood is to pay Ironwood low single digit royalties on the net sales of BNC210, if commercialized. Enormous Short Interest in Bionomics (NASDAQ: BNOX) Increases By a Staggering 20,133% in August Bionomics (NASDAQ: BNOX) was the recipient of a significant increase in short interest in the month of August. As of August 15th, there was short interest totalling 60,700 shares, an increase of 20,133.3% from the July 31st total of 300 shares. Based on an average daily volume of 35,900 shares, the short-interest ratio is presently 1.7 days. 5 Potential Breakout Catalysts That Could Send Shares of Bionomics (NASDAQ: BNOX) Vertical! - (NASDAQ: BNOX) Receives a Staggering $17/share Price Target. - (NASDAQ: BNOX) Collaboration Partnership With Global Giant Merck. - (NASDAQ: BNOX) License Agreement with Ironwood Pharmaceuticals. - (NASDAQ: BNOX) Aggressive Multi Tiered Growth Strategy for 2024. - (NASDAQ: BNOX) Enormous Short Interest 20,133% in August. - (NASDAQ: BNOX) Has Institutional Investment from Hedge Funds. Bionomics (NASDAQ: BNOX) Has Cult Like Following of Analyst [See Proof Here of Analysts]( Multiple equities research analysts have issued 12-month price targets for Bionomics' shares. Their BNOX share price forecasts range from $6.00 to $17.00. On average, they anticipate the company's share price to reach $10.33 in the next twelve months. This suggests a potential upside of 473% from the stock's current price. The Company has taken huge steps forward recently, placing them in an excellent position for rapid growth, all of which indicate the Company's huge growth potential! I am urging all of our members to add (NASDAQ: BNOX) to the top of your watch list right now, and be ready this morning at the opening bell! 10X Your Wealth, Kevin Vander Publisher, 10XProTrader.com Investment Research You are receiving this e-mail as part of your subscription to 10XProTrader. Please do not reply to this e-mail as this address is not monitored. Our Customer Service team is available Monday - Friday between 9:00 AM and 5:00 PM ET. © 2023 10XProTrader.com. All Rights Reserved. Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular inves∙tment situation. N∙o communication by our employees to you should be deemed as personalized financial advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers, prior or during our reporting on the company. © 2023 10XProTrader.com, All Rights Reserved. 10XProTrader is a financial publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or inve∙stment for any specific individual. This communication is a paid a∙dvertisement. 10XProTrader.com and/or its subsidiaries and/or affiliates ("Company," "we," or "us") have been compensated $20,000 USD to disseminate this communication. We have never received stock in BNOX, nor have we traded it. Please note that we do not trade any securities that we profile. We do not hold positions in stocks we profile. We do not except stock as a form of payment for our profiles. Please review the full disc∙laimer at [( for important information about this advertisement. © 2023 10XProTrader. All rights reserved., 340 Royal Poinciana Way Suite 317, 33480, Palm Beach, United States You may [unsubscribe]( or [change your contact details]( at any time.